Hector Chinoy

ORCID, self-asserted

ORCID 0000-0001-6492-1288

Publications

Citations

296

h-index

Computed over the works the graph holds, so it is a floor rather than a career figure.

i10-index

Publications

20 works in the graph, newest first.

Determinants of physical function, as measured using PROMIS PF-10a, in patients with rheumatoid arthritis: results from the international COVID-19 Vaccination in Autoimmune Diseases (COVAD) study
2025University of Debrecen Electronic Archive (University of Debrecen)JournalOpen access0 citations10.1093/rap/rkae154/7934280
Characteristics of emerging new autoimmune diseases after COVID ‐19 vaccination: A sub‐study by the COVAD group
2024International Journal of Rheumatic DiseasesJournalOpen access8 citations10.1111/1756-185x.15178
The impact of multimorbidity on Quality of Life in inflammatory myopathies: A cluster analysis from the COVAD dataset
2024Lara D. VeekenJournalOpen access6 citations10.1093/rheumatology/keae520
Impaired health-related quality of life in idiopathic inflammatory myopathies: a cross-sectional analysis from the COVAD-2 e-survey
2024Rheumatology Advances in PracticeJournalOpen access6 citations10.1093/rap/rkae028
Collating the voice of people with autoimmune diseases: Methodology for the Third Phase of the COVAD Studies
2024Rheumatology InternationalJournalOpen access4 citations10.1007/s00296-024-05562-z
Listening to patients, for the patients: The COVAD Study—Vision, organizational structure, and challenges
2024International Journal of Rheumatic DiseasesJournalOpen access3 citations10.1111/1756-185x.15161
Breakthrough SARS-CoV-2 infection in fully vaccinated patients with systemic lupus erythematosus: results from the COVID-19 Vaccination in Autoimmune Disease (COVAD) study
2024Rheumatology InternationalJournalOpen access1 citations10.1007/s00296-024-05682-6
Determinants of physical function, as measured using PROMIS PF-10a, in patients with rheumatoid arthritis: results from the international COVID-19 Vaccination in Autoimmune Diseases (COVAD) study
2024Rheumatology Advances in PracticeJournalOpen access1 citations10.1093/rap/rkae154
Characteristics of and risk factors for COVID-19 breakthrough infections in idiopathic inflammatory myopathies: results from the COVAD study
2024Lara D. VeekenJournalOpen access1 citations10.1093/rheumatology/keae128
COVID-19 vaccination-related delayed adverse events among people with rheumatoid arthritis: results from the international COVAD survey
2024Rheumatology InternationalJournalOpen access1 citations10.1007/s00296-024-05742-x
Impaired health-related quality of life in idiopathic inflammatory myopathies: a cross-sectional analysis from the COVAD-2 e-survey
2024University of Debrecen Electronic Archive (University of Debrecen)JournalOpen access0 citations10.1093/rap/rkae028/7619044
Vaccine hesitancy decreases in rheumatic diseases, long-term concerns remain in myositis: a comparative analysis of the COVAD surveys
2023Lara D. VeekenJournalOpen access18 citations10.1093/rheumatology/kead057
Flares in IIMs and the timeline following COVID-19 vaccination: a combined analysis of the COVAD-1 and -2 surveys
2023Lara D. VeekenJournalOpen access10 citations10.1093/rheumatology/kead180
Flares after COVID-19 infection in patients with idiopathic inflammatory myopathies: results from the COVAD study
2023Lara D. VeekenJournalOpen access8 citations10.1093/rheumatology/kead149
Flares of autoimmune rheumatic disease following COVID ‐19 infection: Observations from the COVAD study
2023International Journal of Rheumatic DiseasesJournalOpen access7 citations10.1111/1756-185x.14961
COVID-19 Vaccination-Related Delayed Adverse Events among Patients with Systemic Lupus Erythematosus
2023Journal of Clinical MedicineJournalOpen access4 citations10.3390/jcm12247542
COVID-19 vaccine safety during pregnancy and breastfeeding in women with autoimmune diseases: results from the COVAD study
2023Lara D. VeekenJournalOpen access4 citations10.1093/rheumatology/kead382
Delayed adverse events following COVID-19 vaccination in patients with systemic sclerosis and other autoimmune diseases: a substudy of the COVAD-2 cohort
2023Rheumatology InternationalJournalOpen access3 citations10.1007/s00296-023-05441-z
LO-019 Breakthrough SARS-CoV-2 infection in fully vaccinated patients with systemic lupus erythematosus: results from the COVID-19 vaccination in autoimmune disease (COVAD) study
2023PublicationOpen access0 citations10.1136/lupus-2023-kcr.19
COVAD survey 2 long-term outcomes: unmet need and protocol
2022Rheumatology InternationalJournalOpen access44 citations10.1007/s00296-022-05157-6